Nucleoside transport and its significance for anticancer drug resistance.
about
Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 ÅStructural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transportersNew challenges in perioperative management of pancreatic cancerFunctional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocationMolecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brainIdentification of Cys140 in helix 4 as an exofacial cysteine residue within the substrate-translocation channel of rat equilibrative nitrobenzylthioinosine (NBMPR)-insensitive nucleoside transporter rENT2Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosisInhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeuticsIdentification of amino acid residues responsible for the pyrimidine and purine nucleoside specificities of human concentrative Na(+) nucleoside cotransporters hCNT1 and hCNT2Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease.The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms.Telomerase and telomeres: from basic biology to cancer treatment.Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression.Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies.Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma UndergoiMediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptorHuman Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.Human nucleoside transporters: biomarkers for response to nucleoside drugs.Challenges of drug resistance in the management of pancreatic cancer.Nucleoside transporters: biological insights and therapeutic applications.Adjuvant therapy for pancreas adenocarcinoma.Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.Identification of a nucleoside/nucleobase transporter from Plasmodium falciparum, a novel target for anti-malarial chemotherapyCysteine-accessibility analysis of transmembrane domains 11-13 of human concentrative nucleoside transporter 3.Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole.An ancient prevertebrate Na+-nucleoside cotransporter (hfCNT) from the Pacific hagfish (Eptatretus stouti).Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in Saccharomyces cerevisiae.Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in Saccharomyces cerevisiae.Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes.Functional redundancy of two nucleoside transporters of the ENT family (CeENT1, CeENT2) required for development of Caenorhabditis elegans.Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry.
P2860
Q27677998-0055D5A1-E080-4BF3-AA05-B72A848D5052Q27684896-4CE9C073-23CF-4750-AD82-313D0957003DQ28082422-FCFD73D3-3D9F-4638-BABE-6FAE50998851Q28217218-EA59E733-F45F-4DFC-9004-1AC7F6321F56Q28344960-4C05644B-2C22-4B89-9E05-9887517B938CQ28345550-33D64AEF-7878-4E0E-9E71-4D12E154B530Q28377219-BD8D71D1-9F0B-488D-8C2A-BDCFACDEFE81Q28483881-D4BB4899-75D2-4743-B7E5-3543222BCB79Q28487715-A5802E21-0E3E-4B92-B820-8E7B729AED57Q28610373-3CAFDA69-9D31-4398-9E41-A4EC25F5775DQ33337520-C721DA67-A36A-4384-BBD6-B5DB2D256AF2Q34155353-55B1496C-646D-4C09-8939-AC35D2347FC5Q34276389-ACAC0A51-7F36-443F-8710-E727B81AF6A4Q34538689-16E23A5C-95D6-4B00-B20A-761C21FE9CA2Q34651059-C9C3020B-D9F4-41C4-A537-DA02F126B6B6Q35086475-6B86D965-BC80-4C9B-AC72-B449C700124CQ35198909-5F15C651-3DF4-4487-AB21-1987CF71EB95Q35297202-9C444AAD-2990-49F1-B20B-A853BBA599DBQ36342657-AC223D75-A177-498B-9A7D-5A54C57B4A1CQ36822149-35415B46-3C28-465B-9ED0-C0BE199F7470Q36987105-0918F0C4-C70D-421D-B912-DAB08B2EBAAFQ37342736-3A64DC75-8BD3-4E95-8E96-079F15C17869Q37698437-0E99F8C2-9BF3-46A3-A2CB-A94E842B4AA6Q37799830-589E39AB-8CC4-4916-B37F-576A520AB21AQ38031634-61813985-27A9-4F91-BE6B-A9F9FE724470Q38034110-6CC60617-2172-4F3B-AF1E-7397D8A277C7Q38075827-9BFB87D5-324C-4AAF-9CB5-E6E2E5E45148Q38326947-628F98A2-EA3C-4C2C-B2B3-1F9E5DA338D7Q38402177-667B3048-2BA8-4C72-8D03-9330A5EF91DDQ40756087-55824849-5C17-4A19-A1C9-50EE7BCC2FA7Q41816813-3CE0D9A8-6D81-4470-B4E3-60B81957B863Q42078201-8FD37011-377F-4D91-B0E3-75246C6D0D40Q43246854-561BF522-8EF2-476A-ABDD-AE0F7EF2C3C3Q43786796-4E3CD087-A9B2-4C05-954E-935C6A322F1BQ44021405-C7AFDDE9-FEED-42F1-A0D0-8ACD5E403831Q44221920-671F5297-C24D-406B-947D-27212F045D9FQ44813632-81594991-D64F-4F2D-B497-134B48FE3685Q44934641-E1A01FB0-B8C8-42E6-9F37-04A514DE7685Q45061507-87E47BDB-DB30-4BAC-8CA9-C4D182088F45Q45141158-4313E56E-03FC-41C9-967E-2AED5560F9F5
P2860
Nucleoside transport and its significance for anticancer drug resistance.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Nucleoside transport and its significance for anticancer drug resistance.
@ast
Nucleoside transport and its significance for anticancer drug resistance.
@en
type
label
Nucleoside transport and its significance for anticancer drug resistance.
@ast
Nucleoside transport and its significance for anticancer drug resistance.
@en
prefLabel
Nucleoside transport and its significance for anticancer drug resistance.
@ast
Nucleoside transport and its significance for anticancer drug resistance.
@en
P2093
P1476
Nucleoside transport and its significance for anticancer drug resistance.
@en
P2093
P304
P356
10.1016/S1368-7646(98)80047-2
P577
1998-01-01T00:00:00Z